Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference
10 mars 2022 16h01 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
07 mars 2022 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene
10 févr. 2022 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study...
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
24 janv. 2022 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research...
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
20 janv. 2022 17h48 HE
|
Opiant Pharmaceuticals, Inc.
Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels1 Trial is informed by results from Phase 1 studies that showed...
Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today
20 janv. 2022 17h45 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to...
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 déc. 2021 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat...
Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
11 nov. 2021 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference
10 nov. 2021 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today...
Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
04 nov. 2021 16h05 HE
|
Opiant Pharmaceuticals, Inc.
Fast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge1 This designation enables early...